SHIP: association between mean probing depth (quintiles) and anti-PF4/heparin-ELISA ODs assessed with linear regression
| . | Mean probing depth, mm . | P for linear trend . | ||||
|---|---|---|---|---|---|---|
| Q1 (1.04-1.95 mm) . | Q2 (1.95-2.25 mm) . | Q3 (2.25-2.53 mm) . | Q4 (2.54-3.00 mm) . | Q5 (3.02-9.25 mm) . | ||
| IgG | ||||||
| M1 | 0.000 | 0.004 (−0.015; 0.023) | 0.014 (−0.012; 0.039) | 0.024 (0.003; 0.045)* | 0.040 (0.015; 0.064)† | .001 |
| M2 | 0.000 | 0.002 (−0.018; 0.022) | 0.015 (−0.013; 0.042) | 0.022 (−0.001; 0.044) | 0.044 (0.017; 0.070)† | .001 |
| M3 | 0.000 | 0.004 (−0.015; 0.023) | 0.014 (−0.011; 0.039) | 0.024 (0.003; 0.045)* | 0.037 (0.012; 0.061)† | .002 |
| M4 | 0.000 | 0.003 (−0.014; 0.019) | 0.007 (−0.015; 0.029) | 0.021 (0.003; 0.040)* | 0.041 (0.018; 0.064)† | < .001 |
| IgA | ||||||
| M1 | 0.000 | 0.002 (−0.007; 0.011) | 0.005 (−0.004; 0.014) | 0.018 (0.007; 0.028)† | 0.024 (0.012; 0.036)‡ | < .001 |
| M2 | 0.000 | −0.000 (−0.010; 0.009) | 0.004 (−0.006; 0.014) | 0.016 (0.004; 0.027)* | 0.024 (0.012; 0.037)‡ | < .001 |
| M3 | 0.000 | 0.001 (−0.008; 0.010) | 0.004 (−0.005; 0.014) | 0.016 (0.005; 0.027)† | 0.022 (0.010; 0.035)† | < .001 |
| M4 | 0.000 | 0.001 (−0.008; 0.010) | 0.005 (−0.005; 0.014) | 0.015 (0.005; 0.026)† | 0.024 (0.012; 0.036)‡ | < .001 |
| IgM | ||||||
| M1 | 0.000 | 0.006 (−0.019; 0.031) | −0.004 (−0.027; 0.019) | 0.020 (−0.006; 0.047) | 0.058 (0.029; 0.087)‡ | .001 |
| M2 | 0.000 | 0.002 (−0.025; 0.029) | −0.000 (−0.026; 0.025) | 0.013 (−0.017; 0.043) | 0.061 (0.029; 0.093)† | .002 |
| M3 | 0.000 | 0.003 (−0.022; 0.028) | −0.009 (−0.033; 0.014) | 0.013 (−0.014; 0.039) | 0.051 (0.022; 0.081)† | .004 |
| M4 | 0.000 | 0.001 (−0.022; 0.024) | −0.002 (−0.025; 0.020) | 0.017 (−0.008; 0.042) | 0.059 (0.030; 0.087)‡ | < .001 |
| . | Mean probing depth, mm . | P for linear trend . | ||||
|---|---|---|---|---|---|---|
| Q1 (1.04-1.95 mm) . | Q2 (1.95-2.25 mm) . | Q3 (2.25-2.53 mm) . | Q4 (2.54-3.00 mm) . | Q5 (3.02-9.25 mm) . | ||
| IgG | ||||||
| M1 | 0.000 | 0.004 (−0.015; 0.023) | 0.014 (−0.012; 0.039) | 0.024 (0.003; 0.045)* | 0.040 (0.015; 0.064)† | .001 |
| M2 | 0.000 | 0.002 (−0.018; 0.022) | 0.015 (−0.013; 0.042) | 0.022 (−0.001; 0.044) | 0.044 (0.017; 0.070)† | .001 |
| M3 | 0.000 | 0.004 (−0.015; 0.023) | 0.014 (−0.011; 0.039) | 0.024 (0.003; 0.045)* | 0.037 (0.012; 0.061)† | .002 |
| M4 | 0.000 | 0.003 (−0.014; 0.019) | 0.007 (−0.015; 0.029) | 0.021 (0.003; 0.040)* | 0.041 (0.018; 0.064)† | < .001 |
| IgA | ||||||
| M1 | 0.000 | 0.002 (−0.007; 0.011) | 0.005 (−0.004; 0.014) | 0.018 (0.007; 0.028)† | 0.024 (0.012; 0.036)‡ | < .001 |
| M2 | 0.000 | −0.000 (−0.010; 0.009) | 0.004 (−0.006; 0.014) | 0.016 (0.004; 0.027)* | 0.024 (0.012; 0.037)‡ | < .001 |
| M3 | 0.000 | 0.001 (−0.008; 0.010) | 0.004 (−0.005; 0.014) | 0.016 (0.005; 0.027)† | 0.022 (0.010; 0.035)† | < .001 |
| M4 | 0.000 | 0.001 (−0.008; 0.010) | 0.005 (−0.005; 0.014) | 0.015 (0.005; 0.026)† | 0.024 (0.012; 0.036)‡ | < .001 |
| IgM | ||||||
| M1 | 0.000 | 0.006 (−0.019; 0.031) | −0.004 (−0.027; 0.019) | 0.020 (−0.006; 0.047) | 0.058 (0.029; 0.087)‡ | .001 |
| M2 | 0.000 | 0.002 (−0.025; 0.029) | −0.000 (−0.026; 0.025) | 0.013 (−0.017; 0.043) | 0.061 (0.029; 0.093)† | .002 |
| M3 | 0.000 | 0.003 (−0.022; 0.028) | −0.009 (−0.033; 0.014) | 0.013 (−0.014; 0.039) | 0.051 (0.022; 0.081)† | .004 |
| M4 | 0.000 | 0.001 (−0.022; 0.024) | −0.002 (−0.025; 0.020) | 0.017 (−0.008; 0.042) | 0.059 (0.030; 0.087)‡ | < .001 |
Coefficients with 95% CI are presented (n = 3500). M1: adjusted for age (5-year categories) and sex. M2: M1, excluding hospital stays during the last 12 months (n = 494 subjects excluded). M3: M1, plus hs-CRP, leukocytes and fibrinogen (Clauss) included as quintiles (n = 68 subjects with missing data excluded). M4: M1, PF4/heparin EIA OD > 0.5 and OD inhibited > 40% by high heparin (n = 106 subjects excluded).
SHIP indicates Study of Health in Pomerania; Q, quintile; CI, confidence interval; and hs-CRP, high-sensitive C-reactive protein.
P < .05;
P < .01; and
P < 0.001 compared to the first quintile.